ライフサイエンスコーパス: CMV

1 CMV cell-mediated immunity (CMV-CMI) as determined by a

2 CMV clearance was observed after 17.7 +/- 12.6 weeks des

3 CMV has been proposed to play a role in cancer progressi

4 CMV is an obligate and persistent intracellular pathogen

5 CMV reactivation occurred earlier in cyclosporine A-trea

6 CMV reactivation occurred in 100% of seropositive animal

7 CMV reads were identified in 120 (5.4%) samples.

8 CMV seronegative kTx recipients were included.

9 CMV viral load could be decreased and cleared subsequent

10 CMV viremia was associated with an over 2-fold higher mo

11 CMV-CMI was characterized as high when the intermediate-

12 CMV-infection and -disease were successfully managed wit

13 Among 308 CMV seronegative recipients, 168 CMV high-risk and 203 belatacept-treated patients were i

14 tive therapy vs antiviral prophylaxis in 205 CMV-seronegative liver transplant recipients with seropo

15 including asymptomatic CMV viremia (n = 3), CMV syndrome (n = 1), and CMV pneumonitis and colitis (n

16 Among 308 CMV seronegative recipients, 168 CMV high-risk and 203 b

17 01 (27%) developed the composite outcome (61 CMV, 3 HSV/VZV, 19 BSI, 10 IFI, 8 deaths).

18 A CMV polymerase chain reaction assay was developed and ru

19 These results support development of a CMV-specific CAR for therapeutic use against CMV and pot

20 hly correlated (R(2) > 0.99, p < 0.001) to a CMV-qPCR assay conducted on DNA isolated from whole bloo

21 enhancer for plasmid pCMV-ABCA4-SV40 with a CMV promoter.

22 However, what impact acute CMV infection would have on the maintenance of establish

23 lerance model to examine the impact of acute CMV infection on: (a) disruption of established transpla

24 ntenance is disrupted by an episode of acute CMV infection.

25 We demonstrated that acute CMV infection abrogated transplantation tolerance during

26 ed for prophylaxis of CMV infection in adult CMV-seropositive recipients of allogeneic hematopoietic

27 in CMV-seropositive human donors may affect CMV-specific CD8 T cells.

28 ether neutralizing antibodies (nAbs) against CMV pentameric complex (PC)-mediated epithelial cell ent

29 rs were not significantly protective against CMV infection later after HCT in both study arms.

30 CMV-specific CAR for therapeutic use against CMV and potentially other applications harnessing CMV-dr

31 We evaluated the Alethia CMV assay, a rapid, easy-to-use loop-mediated isothermal

32 Among CMV-infected patients, each log2 increase in nAb titer w

33 Among CMV-seronegative liver transplant recipients with seropo

34 Triplex elicited and amplified CMV-specific immune responses, and fewer Triplex-vaccina

35 On multivariable analysis, CMV-CMI, sex, race, antithymocyte globulin, and steroid

36 ruct CMV haplotypes, we demonstrate anatomic CMV compartmentalization in five HIV-infected mothers an

37 Data showing inhibition of HSV-1 and CMV replication, when GA is administered post-infection,

38 V viremia (n = 3), CMV syndrome (n = 1), and CMV pneumonitis and colitis (n = 1).

39 ion was monitored through flow cytometry and CMV viremia was tracked via quantitative polymerase chai

40 lence of periodontal viruses such as EBV and CMV in CAD patients with periodontitis suggesting it as

41 Periodontal viruses such as EBV and CMV were significantly higher (62.5% and 75% respectivel

42 CMV-specific T cell immunity was evident and CMV-specific ACT may trigger a bystander effect leading

43 r morbidities and accumulate in both HIV and CMV infections, both of which are associated with increa

44 costs of implementation of the strategy and CMV disease treatment-related costs.

45 ere observed for levels of anti-MeV and anti-CMV, respectively.

46 We created 8 novel CARs using anti-CMV neutralizing antibody sequences, which were transduc

47 th clinically relevant CMV infection and any CMV infection as time-dependent variables.

48 The CS-CMVi was defined as CMV viremia and/or disease necessitating antiviral thera

49 All models assumed CMV vaccination would prevent primary infection and 2 mo

50 sistant CMV infection including asymptomatic CMV viremia (n = 3), CMV syndrome (n = 1), and CMV pneum

51 The traditional view attributes CMV reactivation and the ensuing clinical disease primar

52 re treated with in vitro-expanded autologous CMV-specific T cells.

53 Baseline CMV serology, and STI-incidence/-seroprevalence, sexual

54 echanisms underlying the association between CMV (and possibly other herpesviruses) and HIV persisten

55 Blood CMV viral load was negative in significantly more immuno

56 Cox models were used to compare outcomes by CMV risk and immunosuppressive regimen.

57 ing deceased kidney donors and recipients by CMV serostatus.

58 ssibility of recipient allo-sensitization by CMV-mediated disruption of stable tolerance.

59 Undetectable viral load by cobas CMV at end of treatment was associated with reduced risk

60 Cytomegalovirus remained detectable by cobas CMV in 44.2% of patients at the time of viral clearance

61 emia was detected 11.5 days earlier by cobas CMV, whereas clearance was delayed by 12.8 days.

62 for use on the cobas 6800/8800 System (cobas CMV) compared with Cobas AmpliPrep/Cobas TaqMan CMV Test

63 verall were 0.29 log IU/mL higher with cobas CMV for use on the cobas 6800/8800 System (cobas CMV) co

64 an average 0.2 log10 decrease in concurrent CMV viral load after infection (P = .001; adjusted for s

65 Congenital CMV infection (cCMVi) affects 0.5-1% of all live births

66 protect the fetus from acquiring congenital CMV infection (cCMV).

67 immunize women to protect against congenital CMV disease and to prevent the consequences of CMV disea

68 However, treatment strategies for congenital CMV (cCMV) infection during pregnancy remain elusive.

69 idence of disease, especially for congenital CMV.

70 act of vaccination for preventing congenital CMV infection.

71 ory abnormalities in infants with congenital CMV infection born to mothers with nonprimary CMV infect

72 Rbm24-targeted deletion using a constitutive CMV-driven Cre in mouse, and rbm24a-CRISPR/Cas9-targeted

73 bas AmpliPrep/Cobas TaqMan CMV Test (CAP/CTM CMV).

74 of viral clearance as determined by CAP/CTM CMV.

75 Cytomegalovirus (CMV) can cause severe disease in children and adults wit

76 Cytomegalovirus (CMV) infection is a serious complication in immunosuppre

77 Cytomegalovirus (CMV) infection remains an important cause of morbidity a

78 Cytomegalovirus (CMV) is a major cause of infection-related morbidity and

79 Cytomegalovirus (CMV) is the commonest cause of congenital infection and

80 Cytomegalovirus (CMV) is the most common congenital infection and infecti

81 Cytomegalovirus (CMV) remains an important pathogen in the transplant pop

82 Cytomegalovirus (CMV) remains associated with poor outcomes after kidney

83 Cytomegalovirus (CMV) viral loads overall were 0.29 log IU/mL higher with

84 Cytomegalovirus (CMV) viremia may be associated with increased mortality

85 Cytomegalovirus (CMV)-infection remains a major cause of morbidity and mo

86 Letermovir (LET), a cytomegalovirus (CMV) deoxyribonucleic acid (DNA) terminase inhibitor, wa

87 copy under the control of a cytomegalovirus (CMV) promoter confirms autonomous genome replication in

88 previously shown that acute cytomegalovirus (CMV) infection disrupts the induction of transplantation

89 candidate vaccines against cytomegalovirus (CMV) infection and disease are in development.

90 pstein-Barr virus (EBV) and cytomegalovirus (CMV), were detected at comparable levels.

91 ), measles virus (MeV), and cytomegalovirus (CMV).

92 on the association between cytomegalovirus (CMV) infection and cardiac allograft vasculopathy (CAV)

93 Chronic cytomegalovirus (CMV) infection leads to long-term maintenance of extraor

94 We hypothesized that early cytomegalovirus (CMV) infection was associated with increased hospitaliza

95 ents received maribavir for cytomegalovirus (CMV) infection failing conventional therapy (trial 202)

96 lopment of therapeutics for cytomegalovirus (CMV) infections, while progressing, has not matched the

97 Human cytomegalovirus (CMV) infections comprise a leading cause of newborn impa

98 agents artemisinins inhibit cytomegalovirus (CMV) in vitro and in vivo, but their target(s) has been

99 urately diagnose the latent cytomegalovirus (CMV) in healthy individuals, even when using highly hete

100 Infection with multiple cytomegalovirus (CMV) strains (mixed infection) was reported in a variety

101 roved for the prevention of cytomegalovirus (CMV) infection in hematopoietic stem cell transplant pat

102 nt advances in the field of cytomegalovirus (CMV).

103 additional enterovirus, one cytomegalovirus (CMV), and two HHV-6 diagnoses.

104 Maternal preconceptional cytomegalovirus (CMV) immunity does not protect the fetus from acquiring

105 public health burden due to cytomegalovirus (CMV) supports current interest in vaccine development.

106 ant (KT) recipients without cytomegalovirus (CMV) prophylaxis.

107 stein-Barr virus [EBV], and cytomegalovirus [CMV]) have limited breadth and diversity.

108 nic viral infections (i.e., cytomegalovirus [CMV] and Epstein-Barr virus [EBV]).

109 ome of infection (including cytomegalovirus [CMV], herpes simplex I/II or varicella zoster virus [HSV

110 (PC)-mediated epithelial cell entry decrease CMV infection after HCT, samples were analyzed from a ra

111 The derived CMV titer is normalised against the total protein concen

112 sive prenatal aneuploidy screening to detect CMV and precisely measure the length of CMV fragments in

113 11 participants, 52% (58/111) had detectable CMV DNA (median plasma viral load 498 IU/mL, interquarti

114 S and cryptococcal meningitis had detectable CMV viremia.

115 over time among participants with detectable CMV and high-level EBV DNA, while it significantly decli

116 he Tshipidi study in Botswana, we determined CMV infection status by 6 months of age and compared hos

117 Recipients developed CMV viremia during the first month post-BMT.

118 The most significant risk for developing CMV infection after transplant depends upon donor (D) an

119 ry infection, and the majority had different CMV genotypes in different compartments.

120 t's individual risk profile for CMV disease, CMV-specific T-cell reconstitution, CMV viral load, and

121 PET is the dominant CMV prevention strategy in that it was associated with l

122 prevention of CMV disease in high-risk donor CMV seropositive/recipient seronegative.

123 ciated with HHV-6 viremia in high-risk donor CMV-seropositive and recipient CMV-seronegative (D+R-) l

124 s in humans, CD8 T cells proliferated during CMV viremia.

125 li and more robust adaptive responses during CMV infection.

126 ent of maternal HIV infection, but not early CMV infection.

127 ide-based enzyme-linked immunospot (ELISPOT) CMV assay may identify patients at risk for clinically s

128 Mapping TCR clones to common viral epitopes (CMV, EBV, and influenza A) demonstrated that Ag specific

129 prospective multicenter study, we evaluated CMV-CMI every 2 weeks from the pretransplant period unti

130 The primary outcomes were CMV events (CMV DNA level >=1250 IU/mL, CMV viremia requiring antivi

131 These APECs redirect pre-existing CMV immunity against tumor cells in vitro and in mouse c

132 alized adoptive transfer of ex vivo expanded CMV-specific CD8+ T cells has provided proof-of-concept

133 xcluding TL outliers, and when adjusting for CMV-seropositivity, HCV-seropositivity, time spent with

134 n of strategy and treatment-related cost for CMV disease, net cost-savings per patient associated wit

135 Treatment decisions for CMV reactivation are becoming increasingly difficult and

136 amples from transplant patients positive for CMV confirmed the extraordinarily short nature of CMV cf

137 s, the patient's individual risk profile for CMV disease, CMV-specific T-cell reconstitution, CMV vir

138 of PET versus valganciclovir prophylaxis for CMV prevention in D+R- liver transplant recipients.

139 Patients at high risk for CMV based on pretransplant CMI developed significantly h

140 to collect than urine and more sensitive for CMV detection than dried blood spots.

141 The 2 main strategies for CMV prevention are prophylaxis and preemptive therapy.

142 aseline plasma samples from 111 subjects for CMV DNA.

143 Saliva is an attractive sample type for CMV testing of newborns, because it is easier to collect

144 ant to recipients of cardiac allografts from CMV-infected donors significantly increased the time to

145 xtending survival of cardiac allografts from CMV-infected donors.

146 Median cfDNA fragment size derived from CMV was significantly shorter than cfDNA derived from hu

147 suggest that these mAb may protect mice from CMV infection via passive immunity.

148 ve study included patients diagnosed with GI-CMV infection at Siriraj Hospital (Bangkok, Thailand) du

149 s, and fewer Triplex-vaccinated patients had CMV viremia.

150 nd potentially other applications harnessing CMV-driven immunotherapies.

151 rimarily by more hospitalizations and higher CMV disease-associated costs due to delayed onset post-p

152 sex partners, and partly explained by higher CMV seroprevalence in MSM.

153 ransplant CMI developed significantly higher CMV infection rates than those deemed to be at low risk

154 totoxic CD4 T cells contribute to CVD in HIV/CMV coinfection and in atherosclerosis via CX3CR1-mediat

155 may help bridge the gap in understanding how CMV infection and immunity are linked to increased cardi

156 However, CMV has been increasingly studied as a cancer vaccine ve

157 of vimentin, depending on the stage of human CMV (HCMV) replication.

158 Infection with the human CMV associates with phenotypic alterations in lymphocyte

159 mycin but lower capacity to respond to human CMV-infected cells; 2) term pregnancy dNK are not skewed

160 We identified CMV in patients undergoing diagnostic rWGS by matching r

161 analysis of patient genetic data to identify CMV, which could impact treatment of up to 4% of childre

162 In this study, we identify CMV coinfection as a major driver of the cytotoxic pheno

163 The pathogenesis of idiopathic CMV disease is unknown.

164 CMV cell-mediated immunity (CMV-CMI) as determined by a peptide-based enzyme-linked

165 d vaccinia Ankara) expressing immunodominant CMV antigens.

166 isk CMV seroprofiles and potentially improve CMV-related outcomes in kidney transplantation.

167 alyzed if the altered NK cell compartment in CMV-seropositive human donors may affect CMV-specific CD

168 We review recent developments in CMV immune monitoring, vaccination, and monoclonal antib

169 A highly reproducible finding in CMV-seropositive individuals is an expansion of NKG2C(po

170 cant trend towards a lower graft survival in CMV high-risk patients treated with belatacept and wheth

171 fusion is necessary and sufficient to induce CMV reactivation following murine transplantation of a l

172 The infants' CMV infection status was not associated with clinical or

173 Overall, 172 cleared their CMV infection (CMV DNA <200 copies/mL) within 6 weeks.

174 we generated a novel RGS12 global knockout (CMV(Cre/+); RGS12(fl/fl)) mouse model by crossing RGS12(

175 ng-term maintenance of extraordinarily large CMV-specific T cell populations.

176 ulation significantly associated with latent CMV infection, confirming the findings in previous studi

177 SPCs per 250 000 cells (cutoff 2), and a low CMV-CMI when SPCs were below these thresholds.

178 tality (P = .007), especially those with low CMV-CMI (P = .035).

179 e of cCMV increases with increasing maternal CMV seroprevalence, the vast majority of the cases of cC

180 were CMV events (CMV DNA level >=1250 IU/mL, CMV viremia requiring antiviral treatment, or end-organ

181 We developed an assay to monitor CMV in Cynomolgus macaques.

182 Monitoring CMV-specific CMI soon after transplantation further defi

183 Similarly, mouse CMV (MCMV) replication in vimentin knockout mice is sign

184 specific for a viral immunoevasin, the mouse CMV m12 protein, and suggest that these mAb may protect

185 se in numbers following infection with mouse CMV (MCMV).

186 Infection with multiple CMV genotypes was common during primary infection and fu

187 isions made during the acute phase of murine CMV infection can alter the level of memory inflation by

188 (Nos2) are susceptible to the related murine CMV infection.

189 tions in recipient mice infected with murine CMV (MCMV) expressing the cognate Ag OVA.

190 nct cell types that are infected with murine CMV (MCMV).

191 sk of acquisition of an exogenous nonprimary CMV infection and fetal transmission.

192 MV infection born to mothers with nonprimary CMV infection are similar to infants born after a primar

193 Activation of CMV-specific CD8 T cells with the cognate Ag further inc

194 The cost of treating a case of CMV disease in our patients was $88,190.

195 V disease and to prevent the consequences of CMV disease in recipients of transplanted organs or hema

196 fication method for qualitative detection of CMV DNA in neonatal saliva samples.

197 ational clinical data linking development of CMV reactivation with worse outcomes in patients in the

198 iclovir prophylaxis, a significant effect of CMV infection on the risk of CAV was seen only among HTx

199 entional trials that examined the effects of CMV prevention.

200 ich may negatively regulate the expansion of CMV-specific CD8 T cells upon activation.

201 However, the exact frequency of CMV nonprimary infection in seroimmune women during preg

202 rophylaxis, resulted in a lower incidence of CMV disease over 12 months.

203 The incidence of CMV disease was significantly lower with preemptive ther

204 The lower-than-expected incidence of CMV events in the placebo group reduced the power of the

205 The detected incidence of CMV resistance among subjects who received LET as prophy

206 h belatacept presented a higher incidence of CMV viremia, a higher rate of first-line treatment failu

207 ed after 17.7 +/- 12.6 weeks despite lack of CMV-immunity.

208 tect CMV and precisely measure the length of CMV fragments in human plasma.

209 Management of CMV required treatment before viremia reached 10 000 cop

210 Measurement of CMV-CMI using a novel ELISPOT assay would be useful clin

211 w that these high-resolution measurements of CMV DNA fragment size accurately predict measured discre

212 light the exceptionally fragmented nature of CMV cfDNA and illustrate the promise of plasma cfDNA seq

213 onfirmed the extraordinarily short nature of CMV cfDNA fragment size with a median length of 149 bp.

214 Incidence and persistence of CMV viremia under belatacept vs tacrolimus were compared

215 We demonstrated that the presence of CMV and high-level EBV DNA in peripheral blood cells was

216 y (PET) or prophylaxis for the prevention of CMV disease in high-risk donor CMV seropositive/recipien

217 apeutics for the treatment and prevention of CMV disease in this population.

218 definitively determine whether prevention of CMV reactivation improves clinical outcomes of patients

219 or, was recently approved for prophylaxis of CMV infection in adult CMV-seropositive recipients of al

220 associated with a 10% lower absolute rate of CMV disease (9% vs 19%).

221 n that it was associated with lower rates of CMV disease and lower overall costs compared to prophyla

222 Reactivation of CMV occurred in 5 Triplex (9.8%) and 10 placebo (19.6%)

223 Reconstitution of CMV-specific T cell immunity was evident and CMV-specifi

224 ATG dose was associated with a lower risk of CMV infection (adjusted hazard ratio [aHR]: 0.63; 95% co

225 e used Cox regression to compare the risk of CMV infection and acute rejection (AR) among KT recipien

226 xis, a single ATG dose decreased the risk of CMV infection without increasing the risk of AR or compr

227 hether it is explained by the higher risk of CMV reactivation and infection.

228 MV UL56 and UL89 genes, encoding subunits of CMV DNA terminase, were sequenced from plasma collected

229 who received letermovir for the treatment of CMV infection from November 2017 to October 2018.

230 vir for both the prevention and treatment of CMV infections and disease in transplant recipients has

231 ess, recent developments in the treatment of CMV infections have resulted in improved human health an

232 ay to monitor the incidence and treatment of CMV viremia in a Cynomolgus macaque model of bone marrow

233 alyzed from a randomized controlled trial of CMV intravenous immunoglobulin (IVIG) prophylaxis.

234 The impact of belatacept on CMV infection remains understudied.

235 , it does support the theory that persistent CMV and EBV shedding could contribute to the dynamics of

236 Whether persistent CMV/EBV replication could be targeted as a strategy to r

237 t CMV infection was defined as either plasma CMV DNAemia >= 1000 IU/mL with/without clinical symptoms

238 apart) for viremia detected by weekly plasma CMV polymerase chain reaction for 100 days (n = 100) or

239 ion in 241 allo-HCT recipients with positive CMV serostatus.

240 ganization (OPO) began a novel pretransplant CMV prevention strategy via matching deceased kidney don

241 Prophylaxis effectively prevents CMV infection after solid organ transplantation (SOT) bu

242 ant depends upon donor (D) and recipient (R) CMV serostatus.

243 gh-risk donor CMV-seropositive and recipient CMV-seronegative (D+R-) liver transplant recipients in t

244 disease, CMV-specific T-cell reconstitution, CMV viral load, and the potential drug resistance detect

245 Using newly developed tools to reconstruct CMV haplotypes, we demonstrate anatomic CMV compartmenta

246 who cleared, but later experienced recurrent CMV infection while on maribavir, 23 had available UL97

247 ibavir resistance in patients with recurrent CMV infection while on therapy, or no response to therap

248 tic options for drug-resistant or refractory CMV infection, including maribavir, letermovir, and adop

249 e mixed efficacy in patients with refractory CMV infection suggesting that letermovir may be a useful

250 ified immunosuppression for graft rejection, CMV infection, higher dose of corticosteroids, or prolon

251 model was applied, with clinically relevant CMV infection and any CMV infection as time-dependent va

252 Clinically relevant CMV infection was defined as either plasma CMV DNAemia >

253 During the follow-up, clinically relevant CMV infection was diagnosed in 96 (37%) patients and CAV

254 in the context of a refractory or resistant CMV infection including asymptomatic CMV viremia (n = 3)

255 Resting CMV-specific CD8 T cells were terminally differentiated

256 national level to optimize low and high-risk CMV seroprofiles and potentially improve CMV-related out

257 we show that strain 68-1 rhesus macaque (RM) CMV vaccine vectors expressing HBV Ags engender HBV-spec

258 ed from subjects with clinically significant CMV infection (CS-CMVi).

259 patients at risk for clinically significant CMV infection (CS-CMVi).

260 Upon solubilisation, CMV IgG is determined by an ELISA assay specifically ada

261 eutic potential of cytomegalovirus-specific (CMV-specific) ACT in an adjuvant setting for patients wi

262 on samples we derived age and sex stratified CMV prevalence statistics for Germany, Poland, UK, and C

263 Subclinical CMV and EBV shedding could contribute to the dynamics of

264 linical findings consistent with symptomatic CMV infection.

265 ) compared with Cobas AmpliPrep/Cobas TaqMan CMV Test (CAP/CTM CMV).

266 ual to controls and significantly lower than CMV-specific clones in infectious villitis.

267 This study suggests that CMV can also affect vaccine responses in younger adults

268 This study provides initial support that CMV IVIG prophylaxis moderately enhances PC-entry nAB ac

269 The CMV UL56 and UL89 genes, encoding subunits of CMV DNA te

270 Among the CMV high-risk group, patients treated with belatacept pr

271 on after transplantation further defines the CMV infection prediction risk.

272 The assay accurately delivers the CMV IgG serostatus from dried buccal swab samples for >8

273 Here we describe a method to determine the CMV IgG serostatus from dried buccal swab samples.

274 uracy of the assay in routine operation, the CMV status of 6,518 donors was reassessed by independent

275 tients (4.2%) with reads that aligned to the CMV reference genome.

276 he LET RAVs that were detected mapped to the CMV UL56 gene at positions associated with reduced susce

277 stood, an issue particularly relevant to the CMVs which have broad tissue tropisms.

278 Overall, 172 cleared their CMV infection (CMV DNA <200 copies/mL) within 6 weeks.

279 of HL among neonates with cCMVI compared to CMV-uninfected neonates was 89.5 (95% CI, 39.7-202.0).

280 rsity over time were analyzed in relation to CMV and EBV shedding status.

281 tion in a child with fatal susceptibility to CMV.

282 tted strains, these congenitally transmitted CMV strains showed statistically significant similaritie

283 was well tolerated and effective in treating CMV-infections in lung transplant recipients failing on

284 wer compared with pretransplant levels until CMV reactivation, at which point they increased during t

285 and delivered 281 infants, of whom 108 were CMV infected.

286 nfants and 17 (19.3%) of 88 HUU infants were CMV-infected by 6 months.

287 The primary outcomes were CMV events (CMV DNA level >=1250 IU/mL, CMV viremia requ

288 Nineteen recipients were CMV seropositive before BMT.

289 ed impact in many developing countries where CMV seroprevalence is almost universal.

290 the activation of NK cells in coculture with CMV-specific CD8 T cells promoted a selective loss of HL

291 use pipeline to identify DNA consistent with CMV infection.

292 in this patient until lethal infection with CMV.

293 use model by crossing RGS12(fl/fl) mice with CMV-Cre transgenic mice and then further induced the mic

294 screening (HS) in identifying neonates with CMV-related HL.

295 CAV was seen only among HTx recipients with CMV breakthrough infection.

296 series of 4 lung transplant recipients with CMV-infection and treatment failure upon standard care d

297 ologic characteristics and relationship with CMV, risk factors and impact of HHV-6 viremia with outco

298 survival rates among those with and without CMV viremia.

299 e was safe and effective in patients without CMV prophylaxis.

300 our study of high-risk KT recipients without CMV prophylaxis, a single ATG dose decreased the risk of